非侵襲的がん診断の世界市場

非侵襲的がん診断の世界市場は2030年までに2,243億米ドルに達する見込み

2024年に1,564億米ドルと推定される非侵襲的がん診断の世界市場は、分析期間2024-2030年にCAGR 6.2%で成長し、2030年には2,243億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである免疫化学は、CAGR8.1%を記録し、分析期間終了時には1,005億米ドルに達すると予測されます。臨床微生物学分野の成長率は、分析期間中CAGR 4.0％と推定されます。

米国市場は426億米ドルと推定、中国はCAGR10.1％で成長予測

米国の非侵襲的がん診断市場は2024年に426億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに468億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と6.2%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の非侵襲的がん診断市場- 主要動向と促進要因まとめ

メスや生検針なしでがん検出に革命を起こせるか？

非侵襲的がん診断は、侵襲的な組織生検ではなく、体液や画像を通して悪性腫瘍の早期、正確な発見とモニタリングを可能にすることで、腫瘍学の状況を一変させます。血液、尿、唾液、呼気から発見されるバイオマーカーを活用することで、これらの技術は臨床医が初期の段階でがんを特定することを可能にし、予後を改善し、手術のリスクを軽減します。リキッドバイオプシー、循環腫瘍DNA（ctDNA）分析、エクソソームプロファイリング、分子イメージングなどの技術は、個別化腫瘍学において重要なツールとして台頭してきています。これらのアプローチは、膵臓、卵巣、肺のような、従来の生検ではリスクが高く歩留まりが悪い、アクセスしにくいがんのスクリーニングにおいて特に大きな影響を与えます。

ゲノミクス、プロテオミクス、高度な画像診断の融合は、非侵襲的診断の範囲を単なる検出から腫瘍タイピング、変異プロファイリング、リアルタイムの治療反応モニタリングへと拡大しました。例えば、リキッドバイオプシーは、がんの初期診断だけでなく、治療中の耐性変異の同定や治療後の微小残存病変の追跡にも使用されています。これらの方法は、繰り返し検査、患者の不快感の軽減、迅速な治療という利点を提供し、患者中心の精密ベースのがん治療を重視する傾向に合致しています。これらの方法は、世界中の主要な腫瘍センターで、臨床ガイドラインや試験デザインにますます組み込まれるようになってきています。

なぜ非侵襲的で迅速な診断への需要が世界的に高まっているのか？

非侵襲的診断薬に対する需要は、人口統計学的、臨床的、経済的要因の組み合わせにより急増しています。世界のがん罹患率の上昇、人口の高齢化、早期発見の利点に対する意識の高まりにより、医療システムは拡張性があり、外傷がなく、費用対効果の高いスクリーニングツールの導入を促しています。政府や公衆衛生プログラムは、特に外科的生検施設へのアクセスが制限されている中低所得国において、集団ベースのスクリーニングを拡大するために非侵襲的診断を優先しています。これらのツールは、症状発現前の早期介入の可能性を提供し、それによって末期がん治療の負担を軽減し、生存率を向上させる。

高所得国では、バリュー・ベースのケア・モデルへの移行により、支払者と医療提供者は、不必要な処置、入院、治療の遅れを減らす診断ソリューションを支持せざるを得なくなっています。非侵襲的検査は効率的なリスク層別化を可能にし、高コストの画像診断や探索的手術への依存を減らします。さらに、患者の嗜好が臨床上の選択に影響を与えるようになってきています。痛みや合併症、侵襲的なモニタリングの繰り返しを嫌う人々の間で、低侵襲の選択肢が支持を集めています。肺がんの呼気分析から大腸がんの便DNA検査まで、多様なプラットフォームが、利用しやすい在宅診断ソリューションを求める患者に受け入れられています。

最先端技術はどのように診断精度とアクセシビリティを高めているのか？

次世代シークエンシング（NGS）、デジタルPCR、マイクロ流体工学、機械学習などの先端技術は、非侵襲的がん診断の感度、特異性、拡張性を高めています。NGSベースのリキッドバイオプシーは現在、わずか1mLの血漿から一塩基変異、コピー数変化、融合遺伝子を検出し、包括的な腫瘍プロファイリングを可能にしています。デジタルPCRプラットフォームは、ctDNAの超高感度定量を提供し、比類のない精度で長期モニタリングをサポートします。マイクロ流体チップは、循環腫瘍細胞（CTC）とエクソソームをリアルタイムで分離するために開発されており、分散型検査とポイントオブケア診断をサポートしています。

人工知能（AI）とデータ解析は、非侵襲的スキャンから深い表現型の特徴を抽出するために、ラジオミクスと病理学イメージングに応用されています。ラジオジェノミクスは、画像バイオマーカーとゲノムデータの統合を可能にし、腫瘍の分子サブタイプを非侵襲的に推論します。クラウドに接続された診断プラットフォームは、臨床医が連続血液検査や画像スキャンを使用して、疾患の進行や治療反応を遠隔監視することを可能にします。新興企業や医療技術イノベーターは、多重アッセイ、ウェアラブルセンサー、家庭用診断キットに注力しており、アクセスを民主化し、高リスク集団の積極的ながんサーベイランスを可能にしています。

非侵襲的がん診断市場の急成長の原動力は？

非侵襲的がん診断市場の成長は、世界の腫瘍学エコシステムを再構築しているいくつかの強力な力によって牽引されています。主要な推進力は、早期かつ非侵襲的な検出が治療計画、コンパニオン診断、リアルタイムモニタリングの基礎となる精密医療の採用が拡大していることです。バイオファーマ企業は、標的治療の選択と臨床試験登録の指針となるアッセイを共同開発するため、診断薬企業との提携を増やしており、商業化と償還支援を加速させています。

リキッドバイオプシーや非侵襲的検査が規制機関、臨床学会、支払者に受け入れられてきていることも重要な成長促進要因です。FDAによるctDNAベースのコンパニオン診断薬の早期承認や、CMSによる複数のがん検出検査に対する好意的な償還決定は、市場の可能性を検証し、投資を促進しました。臨床試験や実臨床研究は、早期がんの検出、耐性変異の追跡、治療成績の改善におけるこれらのツールの有用性を実証し続けています。これと並行して、ベンチャーキャピタルからの資金流入とM&Aの活発化が、技術革新と世界市場の拡大に拍車をかけています。

マルチオミクス・プラットフォーム、AI強化診断、分散型サンプル収集の利用拡大も、コスト障壁を低減し、非侵襲的がん診断を外来設定、プライマリケア・クリニック、さらには患者の自宅にさえもたらしています。がん医療が予防、モニタリング、サバイバーシップに焦点を当てた継続的ケアモデルへと移行する中、非侵襲的診断薬は、がんを末期の危機から管理可能な慢性疾患へと変化させる上で中心的な役割を果たすと思われます。強固な研究開発パイプライン、支持的な政策環境、強力な臨床的モメンタムにより、市場は適応症や地域を問わず飛躍的な成長を遂げる態勢が整っています。

セグメント

製品タイプ（免疫化学、臨床微生物学、ポイントオブケア検査、血液学、その他の製品タイプ）、がんタイプ（肺がん、乳がん、固形がん、血液がん、卵巣がん、その他のがんタイプ）、エンドユーザー（病院＆クリニック、診断センター、外来診療、その他のエンドユーザー）

調査対象企業の例（注目の34社）

• Biocept, Inc.
• Caris Life Sciences
• Datar Cancer Genetics
• DELFI Diagnostics
• Exact Sciences Corporation
• Foundation Medicine
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• iCAD, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• Oncocyte Corporation
• Pacific Edge Ltd.
• QIAGEN N.V.
• Roche Diagnostics
• SAGA Diagnostics AB
• Thermo Fisher Scientific
• Veracyte, Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Non-Invasive Cancer Diagnostics Market to Reach US$224.3 Billion by 2030

The global market for Non-Invasive Cancer Diagnostics estimated at US$156.4 Billion in the year 2024, is expected to reach US$224.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Immunochemistry, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$100.5 Billion by the end of the analysis period. Growth in the Clinical Microbiology segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.6 Billion While China is Forecast to Grow at 10.1% CAGR

The Non-Invasive Cancer Diagnostics market in the U.S. is estimated at US$42.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$46.8 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Non-Invasive Cancer Diagnostics Market - Key Trends & Drivers Summarized

Can Cancer Detection Be Revolutionized Without a Scalpel or Biopsy Needle?

Non-invasive cancer diagnostics are transforming the oncology landscape by enabling early, accurate detection and monitoring of malignancies through bodily fluids and imaging, rather than invasive tissue biopsies. Leveraging biomarkers found in blood, urine, saliva, and exhaled breath, these technologies allow clinicians to identify cancers at nascent stages, improving prognosis and reducing procedural risks. Techniques such as liquid biopsies, circulating tumor DNA (ctDNA) analysis, exosome profiling, and molecular imaging are emerging as critical tools in personalized oncology. These approaches are especially impactful in screening hard-to-access cancers like pancreatic, ovarian, and lung, where traditional biopsies pose high risk and low yield.

The convergence of genomics, proteomics, and advanced imaging has expanded the scope of non-invasive diagnostics beyond mere detection to encompass tumor typing, mutation profiling, and real-time treatment response monitoring. Liquid biopsies, for instance, are being used not only for initial cancer diagnosis but also for identifying resistance mutations during therapy and tracking minimal residual disease post-treatment. These modalities offer advantages in repeat testing, reduced patient discomfort, and faster turnaround, aligning with the growing emphasis on patient-centric and precision-based cancer care. They are increasingly being integrated into clinical guidelines and trial designs across major oncology centers worldwide.

Why Is the Demand for Less Invasive, Faster Diagnostics Gaining Ground Globally?

The demand for non-invasive diagnostics is surging due to a combination of demographic, clinical, and economic factors. Globally rising cancer incidence, aging populations, and growing awareness of the benefits of early detection are prompting health systems to adopt screening tools that are scalable, non-traumatic, and cost-effective. Governments and public health programs are prioritizing non-invasive diagnostics to expand population-based screening, especially in low- and middle-income countries where access to surgical biopsy facilities remains limited. These tools offer the possibility of early intervention before symptom onset, thereby reducing the burden of late-stage cancer treatment and improving survival rates.

In high-income countries, the shift toward value-based care models is compelling payers and providers to favor diagnostic solutions that reduce unnecessary procedures, hospitalizations, and treatment delays. Non-invasive tests enable efficient risk stratification and reduce the dependence on high-cost imaging or exploratory surgery. Furthermore, patient preference is increasingly influencing clinical choices-minimally invasive options are gaining traction among individuals wary of pain, complications, and repeated invasive monitoring. From lung cancer breath analysis to stool-DNA testing for colorectal cancer, diverse platforms are being embraced by patients seeking accessible, home-based diagnostic solutions.

How Are Cutting-Edge Technologies Elevating Diagnostic Precision and Accessibility?

Advanced technologies such as next-generation sequencing (NGS), digital PCR, microfluidics, and machine learning are enhancing the sensitivity, specificity, and scalability of non-invasive cancer diagnostics. NGS-based liquid biopsies now detect single nucleotide variants, copy number alterations, and fusion genes from as little as 1 mL of plasma, enabling comprehensive tumor profiling. Digital PCR platforms offer ultra-sensitive quantification of ctDNA, supporting longitudinal monitoring with unmatched precision. Microfluidic chips are being developed to isolate circulating tumor cells (CTCs) and exosomes in real time, supporting decentralized testing and point-of-care diagnostics.

Artificial intelligence (AI) and data analytics are being applied to radiomics and pathology imaging to extract deep phenotypic features from non-invasive scans. Radiogenomics is enabling the integration of imaging biomarkers with genomic data to non-invasively infer molecular subtypes of tumors. Cloud-connected diagnostic platforms allow clinicians to remotely monitor disease progression and therapy response using serial blood tests or imaging scans. Startups and medtech innovators are focusing on multiplexed assays, wearable sensors, and at-home diagnostic kits, democratizing access and enabling proactive cancer surveillance for high-risk populations.

What’s Driving the Breakneck Growth in the Non-Invasive Cancer Diagnostics Market?

The growth in the non-invasive cancer diagnostics market is driven by several powerful forces that are reshaping the global oncology ecosystem. A key driver is the growing adoption of precision medicine, where early, non-invasive detection is foundational to treatment planning, companion diagnostics, and real-time monitoring. Biopharma companies are increasingly collaborating with diagnostic firms to co-develop assays that guide targeted therapy selection and clinical trial enrollment, accelerating commercialization and reimbursement support.

Another crucial growth catalyst is the rising acceptance of liquid biopsies and non-invasive tests by regulatory bodies, clinical societies, and payers. The FDA’s accelerated approvals of ctDNA-based companion diagnostics and CMS’s favorable reimbursement decisions for multi-cancer detection tests have validated market potential and driven investment. Clinical trials and real-world studies continue to demonstrate the utility of these tools in detecting early-stage cancers, tracking resistance mutations, and improving treatment outcomes. In parallel, rising venture capital inflows and M&A activity are fueling innovation and global market expansion.

The expanding use of multi-omics platforms, AI-enhanced diagnostics, and decentralized sample collection is also reducing cost barriers and bringing non-invasive cancer diagnostics to outpatient settings, primary care clinics, and even patients’ homes. As oncology transitions into a continuous-care model focused on prevention, monitoring, and survivorship, non-invasive diagnostics will play a central role in transforming cancer from a late-stage crisis to a manageable chronic condition. With robust R&D pipelines, supportive policy landscapes, and strong clinical momentum, the market is poised for exponential growth across indications and geographies.

SCOPE OF STUDY:

The report analyzes the Non-Invasive Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology, Other Product Types); Cancer Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Other Cancer Types); End-Use (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Biocept, Inc.
• Caris Life Sciences
• Datar Cancer Genetics
• DELFI Diagnostics
• Exact Sciences Corporation
• Foundation Medicine
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• iCAD, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• Oncocyte Corporation
• Pacific Edge Ltd.
• QIAGEN N.V.
• Roche Diagnostics
• SAGA Diagnostics AB
• Thermo Fisher Scientific
• Veracyte, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Non-Invasive Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Early Detection Initiatives and Screening Programs Drives Demand for Non-Invasive Cancer Diagnostics
  • Growing Preference for Liquid Biopsy Over Surgical Procedures Strengthens Market for Blood-Based Diagnostics
  • Advancements in cfDNA, ctDNA, and Exosome Analysis Propel Precision Oncology Adoption
  • Expansion of Multicancer Detection Panels Throws the Spotlight on Pan-Cancer Non-Invasive Testing Platforms
  • Rising Focus on Monitoring Minimal Residual Disease (MRD) Sustains Use in Post-Treatment Surveillance
  • Integration With AI-Powered Biomarker Analysis Enhances Predictive Accuracy and Risk Stratification
  • Increased Use in Companion Diagnostics Supports Targeted Therapy Matching for Personalized Cancer Care
  • OEM Partnerships With Pharma and Diagnostic Labs Accelerate Co-Development of Stratified Screening Solutions
  • Regulatory Approvals for Non-Invasive Assays Support Clinical Expansion in Lung, Breast, and Colorectal Cancer
  • Emergence of Home-Based Sample Collection Kits Expands Access and Convenience for High-Risk Populations
  • Investment in Cancer Moonshot and Global Screening Programs Drives Research Funding for Non-Invasive Tools
  • Challenges in Sensitivity and Specificity of Early-Stage Detection Propel Innovation in Signal Amplification Techniques
  • Expansion of Reimbursement Frameworks in High-Income Countries Enhances Patient Access to Advanced Testing
  • Use of Urine, Saliva, and Breath Biomarkers Expands Sample Collection Modalities
  • Rising Incidence of Cancer in Aging Populations Supports Demand for Less Invasive Monitoring Methods
  • Technological Advancements in NGS and PCR-Based Platforms Reduce Turnaround Time and Cost Per Test
  • Focus on Longitudinal Disease Tracking and Recurrence Prediction Enhances Market for Serial Testing Solutions
  • Emergence of Wearable Biosensor Technologies Opens Future Pathways for Continuous Cancer Monitoring
  • Data Integration With EHR and Oncology Informatics Platforms Supports Clinical Decision-Making
  • OEM Strategies to Expand in Emerging Markets Strengthen Geographic Penetration of Non-Invasive Diagnostics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Non-Invasive Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Immunochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Clinical Microbiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Clinical Microbiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Clinical Microbiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Point of Care Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Point of Care Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Point of Care Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Ambulatory Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Ambulatory Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Ambulatory Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION